title: [Human insulin vs. analogs. What is the cost of supplementary insulin therapy?].
authors.affiliation: Diabeteszentrum Erfurt, Thilmannstrage 25, D-99085 Erfurt. r.lundershausen@gmx.de
authors.forename: R
authors.initials: R
authors.lastname: Lundershausen
authors.forename: F
authors.initials: F
authors.lastname: Potthoff
authors.forename: C
authors.initials: C
authors.lastname: Häuser
authors.forename: M
authors.initials: M
authors.lastname: Kaiser
authors.forename: C
authors.initials: C
authors.lastname: Münscher
mesh_terms: D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000191:economics*; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics*; D061267:Insulin Aspart; D008687:Metformin / Q000008:administration & dosage / Q000191:economics
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart; D008687:Metformin